Article

Akorn files abbreviated application for FDC

Buffalo Grove, IL-Akorn Inc. has submitted the first abbreviated new drug application with the Office of Generic Drugs on behalf of FDC Ltd., India's second-largest manufacturer and marketer of ophthalmic pharmaceutical products.

Buffalo Grove, IL-Akorn Inc. has submitted the first abbreviated new drug application with the Office of Generic Drugs on behalf of FDC Ltd., India's second-largest manufacturer and marketer of ophthalmic pharmaceutical products.

The proposed drug is an ophthalmic solution that FDC will manufacture in a blow-fill-seal container closure system.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting
© 2025 MJH Life Sciences

All rights reserved.